FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146571866> ?p ?o ?g. }

• W2146571866 endingPage "2816" @default.
• W2146571866 startingPage "2809" @default.
• W2146571866 abstract "Background— Microalbuminuria is associated with increased risk of cardiovascular events. We assessed whether therapeutic intervention aimed at lowering urinary albumin excretion would reduce cardiovascular events in microalbuminuric subjects (15 to 300 mg/24 hours). Methods and Results— From the Prevention of Renal and Vascular Endstage Disease (PREVEND) cohort (n=8592), 1439 subjects fulfilled the inclusion criteria of the PREVEND Intervention Trial (PREVEND IT). Of these subjects, 864 were randomized to fosinopril 20 mg or matching placebo and to pravastatin 40 mg or matching placebo. The mean follow-up was 46 months, and the primary end point was cardiovascular mortality and hospitalization for cardiovascular morbidity. Mean age was 51±12 years; 65% of subjects were male, and 3.4% had a previous cardiovascular event. Mean cholesterol level was 5.8±1.0 mmol/L, mean systolic/diastolic blood pressure was 130±18/76±10 mm Hg, and median urinary albumin excretion was 22.8 (15.8 to 41.3) mg/24 hours. The primary end point occurred in 45 subjects (5.2%). Fosinopril reduced urinary albumin excretion by 26% ( P <0.001). Subjects treated with fosinopril showed a 40% lower incidence of the primary end point (hazard ratio 0.60 [95% CI 0.33 to 1.10], P =0.098, log-rank). Pravastatin did not reduce urinary albumin excretion, and subjects treated with pravastatin showed a 13% lower incidence of the primary end point than subjects in the placebo group (0.87 [0.49 to 1.57], P =0.649, log-rank). Conclusions— In microalbuminuric subjects, treatment with fosinopril had a significant effect on urinary albumin excretion. In addition, fosinopril treatment was associated with a trend in reducing cardiovascular events. Treatment with pravastatin did not result in a significant reduction in urinary albumin excretion or cardiovascular events." @default.
• W2146571866 created "2016-06-24" @default.
• W2146571866 creator A5003503629 @default.
• W2146571866 creator A5013622079 @default.
• W2146571866 creator A5033537614 @default.
• W2146571866 creator A5039782389 @default.
• W2146571866 creator A5045497276 @default.
• W2146571866 creator A5065743151 @default.
• W2146571866 creator A5069496306 @default.
• W2146571866 creator A5074566771 @default.
• W2146571866 creator A5075722725 @default.
• W2146571866 creator A5089523236 @default.
• W2146571866 date "2004-11-02" @default.
• W2146571866 modified "2023-10-18" @default.
• W2146571866 title "Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria" @default.
• W2146571866 cites W1519050139 @default.
• W2146571866 cites W1604542334 @default.
• W2146571866 cites W180946569 @default.
• W2146571866 cites W1986924251 @default.
• W2146571866 cites W2011277038 @default.
• W2146571866 cites W2014237787 @default.
• W2146571866 cites W20181957 @default.
• W2146571866 cites W2022061719 @default.
• W2146571866 cites W2025143124 @default.
• W2146571866 cites W2044334355 @default.
• W2146571866 cites W2044773944 @default.
• W2146571866 cites W2056976690 @default.
• W2146571866 cites W2082800289 @default.
• W2146571866 cites W2107031719 @default.
• W2146571866 cites W2123831918 @default.
• W2146571866 cites W2155598961 @default.
• W2146571866 cites W2305118939 @default.
• W2146571866 cites W2324579467 @default.
• W2146571866 cites W2414811446 @default.
• W2146571866 cites W2615684303 @default.
• W2146571866 cites W3021250193 @default.
• W2146571866 cites W4211051145 @default.
• W2146571866 cites W4245133279 @default.
• W2146571866 doi "https://doi.org/10.1161/01.cir.0000146378.65439.7a" @default.
• W2146571866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15492322" @default.
• W2146571866 hasPublicationYear "2004" @default.
• W2146571866 type Work @default.
• W2146571866 sameAs 2146571866 @default.
• W2146571866 citedByCount "487" @default.
• W2146571866 countsByYear W21465718662012 @default.
• W2146571866 countsByYear W21465718662013 @default.
• W2146571866 countsByYear W21465718662014 @default.
• W2146571866 countsByYear W21465718662015 @default.
• W2146571866 countsByYear W21465718662016 @default.
• W2146571866 countsByYear W21465718662017 @default.
• W2146571866 countsByYear W21465718662018 @default.
• W2146571866 countsByYear W21465718662019 @default.
• W2146571866 countsByYear W21465718662020 @default.
• W2146571866 countsByYear W21465718662021 @default.
• W2146571866 countsByYear W21465718662022 @default.
• W2146571866 countsByYear W21465718662023 @default.
• W2146571866 crossrefType "journal-article" @default.
• W2146571866 hasAuthorship W2146571866A5003503629 @default.
• W2146571866 hasAuthorship W2146571866A5013622079 @default.
• W2146571866 hasAuthorship W2146571866A5033537614 @default.
• W2146571866 hasAuthorship W2146571866A5039782389 @default.
• W2146571866 hasAuthorship W2146571866A5045497276 @default.
• W2146571866 hasAuthorship W2146571866A5065743151 @default.
• W2146571866 hasAuthorship W2146571866A5069496306 @default.
• W2146571866 hasAuthorship W2146571866A5074566771 @default.
• W2146571866 hasAuthorship W2146571866A5075722725 @default.
• W2146571866 hasAuthorship W2146571866A5089523236 @default.
• W2146571866 hasBestOaLocation W21465718661 @default.
• W2146571866 hasConcept C10146269 @default.
• W2146571866 hasConcept C126322002 @default.
• W2146571866 hasConcept C126894567 @default.
• W2146571866 hasConcept C134018914 @default.
• W2146571866 hasConcept C142724271 @default.
• W2146571866 hasConcept C168563851 @default.
• W2146571866 hasConcept C203092338 @default.
• W2146571866 hasConcept C204787440 @default.
• W2146571866 hasConcept C207103383 @default.
• W2146571866 hasConcept C27016395 @default.
• W2146571866 hasConcept C27081682 @default.
• W2146571866 hasConcept C2776174234 @default.
• W2146571866 hasConcept C2778163477 @default.
• W2146571866 hasConcept C2779519902 @default.
• W2146571866 hasConcept C2780436477 @default.
• W2146571866 hasConcept C2781203188 @default.
• W2146571866 hasConcept C44249647 @default.
• W2146571866 hasConcept C71924100 @default.
• W2146571866 hasConcept C84393581 @default.
• W2146571866 hasConcept C90924648 @default.
• W2146571866 hasConceptScore W2146571866C10146269 @default.
• W2146571866 hasConceptScore W2146571866C126322002 @default.
• W2146571866 hasConceptScore W2146571866C126894567 @default.
• W2146571866 hasConceptScore W2146571866C134018914 @default.
• W2146571866 hasConceptScore W2146571866C142724271 @default.
• W2146571866 hasConceptScore W2146571866C168563851 @default.
• W2146571866 hasConceptScore W2146571866C203092338 @default.
• W2146571866 hasConceptScore W2146571866C204787440 @default.
• W2146571866 hasConceptScore W2146571866C207103383 @default.
• W2146571866 hasConceptScore W2146571866C27016395 @default.

• next